Stonepine Capital Management LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Stonepine Capital Management LLC acquired a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 55,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,128,000. Jazz Pharmaceuticals accounts for about 3.9% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 4th biggest holding. Stonepine Capital Management LLC owned about 0.09% of Jazz Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of JAZZ. Bridgewater Associates LP raised its stake in shares of Jazz Pharmaceuticals by 11.7% during the 3rd quarter. Bridgewater Associates LP now owns 112,999 shares of the specialty pharmaceutical company’s stock worth $12,589,000 after purchasing an additional 11,864 shares in the last quarter. Townsquare Capital LLC acquired a new position in Jazz Pharmaceuticals in the 3rd quarter valued at $220,000. Loomis Sayles & Co. L P grew its holdings in Jazz Pharmaceuticals by 2.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 106,652 shares of the specialty pharmaceutical company’s stock valued at $11,882,000 after buying an additional 2,838 shares in the last quarter. Cerity Partners LLC grew its holdings in shares of Jazz Pharmaceuticals by 128.4% during the 3rd quarter. Cerity Partners LLC now owns 32,757 shares of the specialty pharmaceutical company’s stock worth $3,650,000 after purchasing an additional 18,414 shares in the last quarter. Finally, Valence8 US LP acquired a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter worth $999,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded down $0.03 during trading on Wednesday, reaching $122.76. 23,814 shares of the stock traded hands, compared to its average volume of 676,025. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company has a 50-day moving average of $114.17 and a 200-day moving average of $110.90. The stock has a market capitalization of $7.42 billion, a P/E ratio of 17.29, a price-to-earnings-growth ratio of 1.05 and a beta of 0.57.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several recent analyst reports. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. TD Cowen decreased their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Finally, Royal Bank of Canada boosted their price objective on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a report on Wednesday, October 23rd. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $175.33.

Insider Activity

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. This represents a 10.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. This represents a 8.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,110 shares of company stock valued at $720,160 in the last 90 days. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.